Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Novonesis (Novozymes) BNVZMF 90 EV-to-OCF is 22.67 as of Sep. 09, 2026, which is 13% below its 10-year median of 25.91. GuruFocus rates NVZMF with a GF Score™ of 90/100 and a GF Value™ of $64.39 (Fairly Valued). The stock has 6 warning signs investors should review. Among 1,616 Chemicals companies, Novonesis (Novozymes) B ranks worse than 71.91% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Novonesis (Novozymes) B's Enterprise Value is $34,813 Mil.
Novonesis (Novozymes) B's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was $1,536 Mil. Therefore, Novonesis (Novozymes) B's EV-to-OCF for today is 22.67.
The historical rank and industry rank for Novonesis (Novozymes) B's EV-to-OCF or its related term are showing as below:
NVZMF'
s EV-to-OCF Range Over the Past 10 Years
Min: 17.73 Med: 25.91 Max: 38.52
Current: 22.67
During the past 13 years, the highest EV-to-OCF of Novonesis (Novozymes) B was 38.52. The lowest was 17.73. And the median was 25.91.
NVZMF's EV-to-OCF is ranked worse than 71.91% of 1616
companies
in the Chemicals industry
Industry Median: 11.45
vs NVZMF: 22.67
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Novonesis (Novozymes) B (OTCPK:NVZMF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Novonesis (Novozymes) B's PE Ratio (TTM) for today is calculated as:
Novonesis (Novozymes) B's share price for today is $66.87.
Novonesis (Novozymes) B's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.579.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, Novonesis (Novozymes) B's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novonesis (Novozymes) B EV-to-OCF vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Novonesis (Novozymes) B's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Novonesis (Novozymes) B's EV-to-OCF falls into.
Novonesis (Novozymes) B's current Enterprise Value is $34,813 Mil.
Novonesis (Novozymes) B's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,536 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Novonesis (Novozymes) B (NVZMF) has a EV-to-OCF of 22.67 as of Sep. 09, 2026. This is 13% below median its historical median of 25.91. Over the past decade, Novonesis (Novozymes) B's EV-to-OCF has ranged from 17.73 to 38.52. According to the industry distribution chart, Novonesis (Novozymes) B ranks #1162 out of 1616 companies in the Chemicals industry, placing it in the top 71.9%.
Is Novonesis (Novozymes) B's EV-to-OCF too high?
Novonesis (Novozymes) B's current EV-to-OCF of 22.67 is 13% below median its 10-year median of 25.91. Over the past 10 years, this metric has ranged from a low of 17.73 to a high of 38.52. The Chemicals industry median EV-to-OCF is 11.45. Novonesis (Novozymes) B's value of 22.67 is 98% above this industry median. Based on the distribution chart, Novonesis (Novozymes) B ranks #1162 out of 1616 companies in the Chemicals industry, which is below the industry midpoint. Overall, Novonesis (Novozymes) B has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Novonesis (Novozymes) B's EV-to-OCF compare to LIN and SHW?
According to the Chemicals industry distribution chart, Novonesis (Novozymes) B ranks #1162 out of 1616 companies for EV-to-OCF. This places Novonesis (Novozymes) B in the lower half of its industry. The industry median EV-to-OCF is 11.45. Novonesis (Novozymes) B's value of 22.67 is 98% above this benchmark. Historically, Novonesis (Novozymes) B's own EV-to-OCF has ranged from 17.73 to 38.52 over the past decade. While the company's 10-year median is 25.91 vs. the industry median of 11.45, Novonesis (Novozymes) B has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Chemicals company?
The median EV-to-OCF among Chemicals companies is 11.45, based on 1,616 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Novonesis (Novozymes) B's current EV-to-OCF of 22.67 is 98% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Chemicals industry, the median EV-to-OCF is 11.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novonesis (Novozymes) B's current EV-to-OCF is 22.67, which is 13% below median its own 10-year median of 25.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novonesis (Novozymes) B stock overvalued right now?
Based on GuruFocus' analysis, Novonesis (Novozymes) B (NVZMF) is currently considered Fairly Valued. The stock's GF Value™ is $64.39, compared to a current price of $66.87 — trading 3.9% above its estimated fair value. The current EV-to-OCF is 22.67, which is 13% below median its 10-year median of 25.91 and 98% above the Chemicals industry median of 11.45. Novonesis (Novozymes) B's overall GF Score™ is 90/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Novonesis (Novozymes) B (NVZMF), the current EV-to-OCF is 22.67 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novonesis (Novozymes) B (NVZMF) Overvalued in 2026?
Based on GuruFocus' analysis, Novonesis (Novozymes) B stock appears to be overvalued.
The current stock price of $66.87 is trading 3.9% above its estimated GF Value™ of $64.39.
GuruFocus considers Novonesis (Novozymes) B to be Fairly Valued.
Key valuation signals for NVZMF:
EV-to-OCF: 22.67 (13% below median its 10-year median of 25.91)
GF Value™: $64.39 vs. price of $66.87 (3.9% above fair value)
Industry Position: 98% above the Chemicals median (#1162 of 1616)
No single metric tells the full story. See the NVZMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novonesis was formed in 2024 through the merger of Novozymes and Chr. Hansen. Following the merger, the company became the world leader in industrial enzymes and microbial solutions, with a nearly 50% market share in both. The firm supplies a wide range of industry groups: household care, food and beverages, bioenergy, agriculture and feed, technical and pharmaceuticals. Its biological solutions create value for its customers by improving yield efficiency and performance, while saving energy and generating less waste. The company is headquartered in Denmark, employs more than 11,000 people, and works across more than 30 research and development and application centers and 23 manufacturing sites.
90GF Score
Get the complete analysis for NVZMF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NVZMF has been successfully added to your 
